论文部分内容阅读
目的探讨细胞因子诱导的杀伤(Cytokine-induced killer cells,CIK)细胞治疗后肿瘤患者的免疫功能改变。方法采用流式细胞术检测28例肿瘤患者经CIK细胞治疗前后外周血CD4+CD25+T细胞比例。结果肿瘤患者CD4+CD25+T细胞比例明显高于对照组(P<0.05)。经CIK细胞治疗后,CD4+CD25+T细胞比例降低,与治疗前比较有统计学意义(P<0.05),但治疗后CD4+CD25+T细胞比例仍高于对照组,且差异有统计学意义(P<0.05)。结论肿瘤患者免疫功能处于抑制状态,CIK细胞治疗能在一定程度上提高患者机体的免疫功能。利用流式细胞术监测患者外周血CD4+CD25+T细胞的变化,对于评价疗效与判断预后具有一定的价值。
Objective To investigate the immune function of tumor patients after cytokine-induced killer (CIK) cell therapy. Methods Flow cytometry was used to detect the percentage of CD4 + CD25 + T cells in peripheral blood of 28 cancer patients before and after CIK cell therapy. Results The proportion of CD4 + CD25 + T cells in tumor patients was significantly higher than that in control group (P <0.05). After treatment with CIK cells, the proportion of CD4 + CD25 + T cells decreased, with statistical significance (P <0.05) before treatment, but the proportion of CD4 + CD25 + T cells after treatment was still higher than that of the control group Significance (P <0.05). Conclusion The immune function of tumor patients is in a state of inhibition. CIK cell therapy can improve the immune function of the patients to a certain extent. Flow cytometry in patients with peripheral blood CD4 + CD25 + T cell changes for the evaluation of efficacy and prognosis of a certain value.